SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

NeOnc Technologies Holdings, Inc. (NTHI) News

Track canonical SquawkNews coverage tagged to NTHI, NeOnc Technologies Holdings, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 27 indexed stories across 19 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol NTHI Asset equity Sector Markets 90 days 25 Last 3.295 Updated Sep 28, 2026, 02:03 PM UTC Open live news feed
L NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 November 17 meeting will address Phase 2 study design and potential regulatory pathwaysCALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a REGULATION | Sep 28, 2026, 02:03 PM UTC L NeOnc Technologies Initiated at Buy by Roth Capital Ratings actions from Benzinga: GMT) NeOnc Technologies Price Target Announced at $20.00/Share by Roth CapitalRatings actions from Benzinga NEWS | Sep 24, 2026, 06:25 PM UTC L NTHI - NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst NTHI - NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst NEWS | Sep 24, 2026, 02:20 PM UTC L NTHI - NeOnc’s Delivery may Finally Change the Equation for Brain Cancer ’s Next Frontier NTHI - NeOnc’s Delivery may Finally Change the Equation for Brain Cancer ’s Next Frontier NEWS | Sep 22, 2026, 06:52 PM UTC L NTHI - NeOnc Charting New Nasal Route to Treating Brain Cancer NTHI - NeOnc Charting New Nasal Route to Treating Brain Cancer NEWS | Sep 21, 2026, 12:00 PM UTC L NTHI - NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution NTHI - NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution EQUITY | Sep 17, 2026, 12:00 PM UTC L NTHI - NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA NTHI - NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA REGULATION | Sep 16, 2026, 12:46 PM UTC L NTHI - NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results NTHI - NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results EQUITY | Sep 16, 2026, 12:00 PM UTC L NTHI - Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus NTHI - Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus NEWS | Sep 15, 2026, 01:53 PM UTC M NeOnc Technologies raises about $15 million via registered direct offering at $4.20 NeOnc Technologies entered securities purchase agreements for a registered direct offering expected to raise approximately $15 million. The offering prices common shares and accompanying warrants at $4.20 and includes 2, EQUITY | Sep 10, 2026, 02:34 PM UTC L NeOnc Technologies prices $15 mln at-the-market offering NeOnc Technologies Holdings priced a $15 million at-the-market offering. EQUITY | Sep 09, 2026, 04:43 PM UTC L NeOnc raises $15 million at market, adding fuel to NEO100 data NeOnc (NTHI) raised $15 million at market. EQUITY | Sep 09, 2026, 01:35 PM UTC M NeOnc Technologies prices $15M registered direct offering NeOnc Technologies Holdings, Inc. priced a $15 million registered direct offering under Nasdaq at-the-market rules. EQUITY | Sep 09, 2026, 12:02 PM UTC L NTHI - NeOnc' Phase 2 Data Could Put Cancer on the Ropes NTHI - NeOnc' Phase 2 Data Could Put Cancer on the Ropes EQUITY | Sep 08, 2026, 12:39 PM UTC L BTIG maintains $15.00 price target on NeOnc Technologies BTIG maintained a $15.00/share price target on NeOnc Technologies, according to Benzinga ratings actions. EQUITY | Sep 08, 2026, 10:57 AM UTC L NTHI - NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger NTHI - NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger EQUITY | Aug 28, 2026, 02:08 PM UTC L NTHI - NeOnc’s Clinical Story Is Now the Main Event NTHI - NeOnc’s Clinical Story Is Now the Main Event EQUITY | Aug 26, 2026, 01:39 PM UTC L NeonC Technologies CEO Amir F P Heshmatpour files Form 4P NeonC Technologies Holdings, Inc. reports a Form 4P filing for CEO, President Amir F P Heshmatpour indicating 9,000 shares at $5.54 for $49,860. EQUITY | Aug 18, 2026, 06:32 PM UTC L NTHI - NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t NTHI - NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t EQUITY | Aug 18, 2026, 02:18 PM UTC L NTHI - NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results NTHI - NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results EQUITY | Aug 17, 2026, 12:45 PM UTC L NTHI - The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech NTHI - The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech EQUITY | Aug 13, 2026, 06:31 PM UTC L NTHI - Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer NTHI - Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer EQUITY | Aug 12, 2026, 01:38 PM UTC M NTHI Trading Resumes NTHI will resume at 8:30 am EQUITY | Aug 12, 2026, 12:04 PM UTC H NTHI Reports Positive Phase 2a Results NTHI reports positive topline Phase 2a results for Intranasal NEO100 EQUITY | Aug 12, 2026, 12:00 PM UTC L NTHI - NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors NTHI - NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors EQUITY | Jul 27, 2026, 01:00 PM UTC H NTHI Gains Momentum NTHI builds regulatory momentum with 4 new research reports and UAE/Dubai drug approval ahead of Phase 2 data EQUITY | Jun 24, 2026, 12:45 PM UTC M NTHI Receives UAE IND Approval NeOnc Technologies receives UAE IND approval for NEO100, expanding global development ahead of anticipated Phase 2 data milestone EQUITY | Jun 23, 2026, 01:01 PM UTC